Cart Icon0
Menu

Search from website

sIgA antibody therapeutics

The current antibody therapeutics market targeting respiratory and gastrointestinal viruses is mostly restricted due to the limitations of IgG molecules and administration by intra-venous injection. 

Icosagen is developing sIgA platform that enables to reformat existing therapeutic antibodies against respiratory and gastrointestinal viruses into an IgA isotype administrated by nebulization. 

Shopping Cart